Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap Down – Time to Sell?

05 Jan 2026, 14:38 by Doug Wharley · The Cerbat Gem

Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report)’s share price gapped down before the market opened on Monday . The stock had previously closed at $140.60, but opened at $136.00. Neurocrine Biosciences shares last traded at $137.8360, with a volume of 328,497 shares changing hands.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on NBIX shares. Mizuho raised their price target on shares of Neurocrine Biosciences from $146.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, December 12th. HC Wainwright increased their target price on Neurocrine Biosciences from $168.00 to $198.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Needham & Company LLC upped their target price on shares of Neurocrine Biosciences from $170.00 to $184.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Citigroup increased their price target on shares of Neurocrine Biosciences from $175.00 to $203.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Finally, TD Cowen boosted their price objective on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, December 5th. Eighteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Neurocrine Biosciences has an average rating of “Moderate Buy” and an average price target of $175.25.

Check Out Our Latest Stock Analysis on NBIX

Neurocrine Biosciences Stock Performance

The business’s 50 day moving average price is $146.96 and its 200-day moving average price is $139.47. The company has a market cap of $13.57 billion, a price-to-earnings ratio of 32.56, a PEG ratio of 0.69 and a beta of 0.28.

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last posted its quarterly earnings results on Tuesday, October 28th. The company reported $2.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.59. The firm had revenue of $794.90 million during the quarter, compared to analyst estimates of $746.61 million. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. The company’s quarterly revenue was up 27.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.81 earnings per share. On average, equities research analysts expect that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider Darin Lippoldt sold 4,376 shares of the stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $159.65, for a total transaction of $698,628.40. Following the completion of the sale, the insider owned 43,405 shares in the company, valued at $6,929,608.25. This trade represents a 9.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director George J. Morrow sold 15,000 shares of the business’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $143.37, for a total transaction of $2,150,550.00. Following the completion of the transaction, the director owned 7,068 shares in the company, valued at approximately $1,013,339.16. This trade represents a 67.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 43,866 shares of company stock worth $6,570,237 over the last three months. 4.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Neurocrine Biosciences

Institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. raised its position in shares of Neurocrine Biosciences by 59.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,261,747 shares of the company’s stock valued at $535,659,000 after acquiring an additional 1,590,749 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Neurocrine Biosciences by 83.7% during the third quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock worth $388,435,000 after purchasing an additional 1,263,633 shares during the period. Norges Bank acquired a new stake in shares of Neurocrine Biosciences during the second quarter worth $122,278,000. Los Angeles Capital Management LLC increased its holdings in Neurocrine Biosciences by 19,454.9% in the second quarter. Los Angeles Capital Management LLC now owns 744,650 shares of the company’s stock valued at $93,595,000 after purchasing an additional 740,842 shares during the last quarter. Finally, Swedbank AB lifted its stake in Neurocrine Biosciences by 5,078.9% in the first quarter. Swedbank AB now owns 429,697 shares of the company’s stock valued at $47,524,000 after buying an additional 421,400 shares during the period. Institutional investors own 92.59% of the company’s stock.

About Neurocrine Biosciences

(Get Free Report)

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.